US20050256079A1 - Process for the manufacture of n-acyl-(epi)k5-amine-o-sulfate-derivatives and products thus obtained - Google Patents

Process for the manufacture of n-acyl-(epi)k5-amine-o-sulfate-derivatives and products thus obtained Download PDF

Info

Publication number
US20050256079A1
US20050256079A1 US10/518,303 US51830305A US2005256079A1 US 20050256079 A1 US20050256079 A1 US 20050256079A1 US 51830305 A US51830305 A US 51830305A US 2005256079 A1 US2005256079 A1 US 2005256079A1
Authority
US
United States
Prior art keywords
amine
acyl
oversulfate
approximately
sulfation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/518,303
Other languages
English (en)
Inventor
Pasqua Oreste
Giorgio Zoppetti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glycores 2000 Srl
Original Assignee
Glycores 2000 Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IT2002MI001346A external-priority patent/ITMI20021346A1/it
Priority claimed from IT2002MI001345A external-priority patent/ITMI20021345A1/it
Priority claimed from ITMI20021854 external-priority patent/ITMI20021854A1/it
Application filed by Glycores 2000 Srl filed Critical Glycores 2000 Srl
Assigned to GLYCORES 2000 S.R.L. reassignment GLYCORES 2000 S.R.L. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ORESTE, PASQUA ANNA, ZOPPETTI, GIORGIO
Publication of US20050256079A1 publication Critical patent/US20050256079A1/en
Priority to US12/120,167 priority Critical patent/US8513407B2/en
Priority to US14/328,271 priority patent/US9346893B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • C08B37/0078—Degradation products

Definitions

  • the present invention concerns new derivatives of K5 polysaccharide with a high degree of sulfation, a process for their preparation, new highly O-sulfated intermediates useful in their synthesis and pharmaceutical compositions containing said derivatives of K5 polysaccharide as active ingredients basically free of activity on coagulation.
  • the invention refers to derivatives of K5 polysaccharide obtained starting with a K5 polysaccharide, previously N-deacetylated, N-sulfated, optionally depolymerized or optionally at least 20% C5-epimerized and optionally depolymerized, by O-oversulfation in suitable conditions and subsequent N-acylation of the free amine.
  • glycosaminoglycans such as heparin, heparan sulfate, dermatan sulfate, chondroitin sulfate and hyaluronic acid are biopolymers extracted industrially from various animal organs.
  • pentasaccharide region of a bond to antithrombin III ATIII
  • active pentasaccharide which is the structure necessary for the high affinity bond of heparin to ATIII and fundamental for anticoagulant and antithrombotic activity of the heparin itself.
  • This pentasaccharide present inside only some of the chains which form heparin, contains a sulfated glucosamine unit in position 3 and a glucuronic acid spaced out between disaccharides containing iduronic acids.
  • the formation of the active pentasaccharide is made possible by the epimerization reaction of the carboxy of a part of the glucuronic units into iduronic units carried out by the glucuronyl-C5-epimerase (C5-epimerization) and by suitable sulfation which also leads to the introduction of a sulfate group on the hydroxyl in position 3 of the glucosamine. More particularly, in nature the formation of the active pentasaccharide is made possible by the fact that C5-epimerization occurs in clusters, i.e. on portions of chains, and extensively which leads to a product which contains more iduronic units than glucuronic ones. In fact, commercial heparin contains approximately 70% of iduronic units and 30% of glucuronic units.
  • capsular K5 polysaccharide isolated from Escherichia coli described by Vann W. F. et al., in European Journal of Biochemistry, 1981, 116, 359-364 (“Vann 1981”), is consisting of a chain mixture consisting of the repetitive disaccharide unit glucuronyl- ⁇ -1 ⁇ 4-N-acetyl glucosamine and therefore shows the same repetitive sequence (A) of N-acetyl-heparosan precursor of heparin.
  • the capsular K5 polysaccharide referred to hereafter as “K5 polysaccharide” or more simply “K5”, was chemically modified by Lormeau et al. as described in U.S. Pat. No.
  • the processes described in IT 1230785, WO 92/17507, WO 96/14425 and WO 97/43317 utilize K5 as the starting material.
  • the K5 originating from fermentation is subjected to N-deacetylation followed by N-sulfation and on the K5-N-sulfate thus obtained C5-epimerization with C5-epimerase in solution is performed, obtained either by chromatography of a solution of microsomal enzymes from mouse mastocytoma (IT 1230 785) or from bovine liver (WO 92/17507, WO 96/14425 and WO 97/43317).
  • the D-glucuronyl C5 epimerase from bovine liver was purified by Campbell, P. et al. in J. Biol. Chem., 1994, 269/43, 26953-26958 (“Campbell 1994”) who also provided its composition in amino acids and described its use in solution for the transformation of a K5-N-sulfate into the corresponding 30% epimerized product, demonstrating the formation of iduronic acid by HPLC method followed by total nitrous depolymerization to disaccharide.
  • the document WO 98/48006 describes the DNA sequence which codes for the D-glucuronyl C5 epimerase and a recombinant D-glucuronyl C5 epimerase, obtained from a recombinant expression vector containing said DNA, afterwards purified by Campbell et al. as shown by Jin-Ping L. et al. in J. Biol. Chem. 2001, 276, 20069-20077 (“Jin-Ping 2001”).
  • the document WO 01/72848 describes a method for the preparation of N-deacetylated N-sulfate derivatives of K5 polysaccharide, at least 40% epimerized of iduronic acid as regards the total of the uronic acids, having a molecular weight from 2000 to 30,000, containing from 25 to 50% of high affinity chains for ATIII and having an anticoagulant and antithrombotic activity expressed as HClI/antiXa ratio from 1.5 to 4.
  • Said document describes the oversulfation of a 40-60% epimerized K5-N-sulfate and shows that the product obtained, whose 13 C-RMN is illustrated, has a sulfate group content per disaccharide unit of 2-3.5.
  • lmw-epiK5-N-sulfate when subjected to the same method of salification and of O-oversulfation gives a lmw-epiK5-amine-O-sulfate with an extremely high degree of sulfation.
  • degree of sulfation is more than 3.2.
  • FIG. 2 shows the NMR proton spectrum of epiK5-N-acetylate, O-sulfate with a sulfate/carboxy ratio of 4.26 (obtained according to Example 2);
  • FIG. 3 shows the NMR proton spectrum of K5-N-acetylate, O-sulfate with a sulfate/carboxy ratio of 2.87 (obtained according to Example 3).
  • the present invention provides a process for the preparation of N-acyl-(epi)K5-amine-O-oversulfate-derivatives, characterized in that
  • chemically acceptable refers to a cation usable in chemical synthesis, such as the ions sodium, ammonium, (C 1 -C 4 )tetraalkylammonium, or for the purification of the product, whereas “pharmaceutically acceptable” is self-explanatory.
  • the step (a) is carried out by passing a solution of the sodium salt of the (epi)K5-N-sulfate-derivative, i.e. of K5 polysaccharide, previously N-deacetylated, N-sulfated preferably 100%, optionally 20-60% C5-epimerized and optionally depolymerized with nitrous acid, having a mean molecular weight from approximately 1,000 to approximately 25,000, advantageously from approximately 1,500 to approximately 25,000, through an acid ionic exchange resin, for example of the type IR-120H + , collecting the eluate including also the washing water of the resin and neutralizing the eluate with tertiary or quaternary organic base, preferably with an aqueous solution of tetrabutylammonium hydroxide.
  • a solution of the sodium salt of the (epi)K5-N-sulfate-derivative i.e. of K5 polysaccharide, previously N-deace
  • step (b) the O-oversulfation occurs utilizing an excess of O-sulfating agent and working at a temperature from 20 to 70° C. for a time period of up to 24 hours in an aprotic polar solvent.
  • a K5-amine-O-oversulfate-derivative having a mean molecular weight from approximately 1,500 to approximately 25,000
  • a K5-amine-O-oversulfate-derivative having a mean molecular weight from approximately 3,500 to 40,000, advantageously from approximately 4,500 to approximately 40,000 and a sulfation degree of at least 2.2, advantageously from 2.2 to 3 or from 2.3 to 3, more advantageously from 2.5 to 3, preferably from 2.7 to 2.9.
  • the product thus obtained comes from a lmw-K5-N-sulfate and is preferably the sodium salt of a lmw-K5-amine-O-oversulfated having a degree of sulfation from 2.3 to 3.
  • the mean molecular weight of such product can be from approximately 3,500 to approximately 11,000.
  • the sodium salt thus obtained can be converted into another salt.
  • calcium ionic exchange can be performed working with an ultrafiltration membrane.
  • step (c) the (epi)K5-amine-O-oversulfate-derivative with a high degree of sulfation is N-acylated utilizing the known methods in literature.
  • the N-acylation is performed by making the (epi)K5-amine-O-oversulfate-derivative originating from step (b) react with a functional derivative of a mono or dicarboxylic acid containing from 2 to 4 carbon atoms in hydroalcoholic solution at a temperature of approximately 4° C.
  • a functional derivative of said (C 2 -C 4 ) carboxylic acids preferably of acetic, propionic, malonic, or succinic acid or of mono esters, in particular methylic or ethylic, of the latter, one can use the anhydride, the chloride, a mixed anhydride or an active ester.
  • N-(C 2 -C 4 )acyl-(epi)K5-amine-O-oversulfate-derivative is neutralized with a base, preferably sodium hydroxide, and then isolated by ultrafiltration and precipitation with a saturated sodium chloride solution in acetone.
  • a base preferably sodium hydroxide
  • the step of N-acylation is repeated until obtaining total substitution or however more than 95%.
  • the new N-acyl-(epi)K5-amine-O-oversulfate-derivatives are generally in their sodium salt forms.
  • Said sodium salt can be converted into another chemically or pharmaceutically acceptable salt.
  • Particularly advantageous salts are those of alkaline metals, alkaline-earth metals, of ammonium, (C 1 -C 4 )tetraalkylammonium, aluminum and zinc.
  • the salts of sodium, calcium and tetrabutylammonium are preferred.
  • the process of the present invention is extremely versatile. In fact, it allows the preparation of N-acyl-K5-amine-O-oversulfates of every type in very high yields, with easily controllable reactions.
  • the process of the present invention allows the preparation of N-acyl-K5-amine-O-oversulfates otherwise unobtainable, like the epimerized C-5 derivatives, the N-acylated derivatives with a different acyl from the acetyl present in the native K5 and the derivatives of low molecular weight.
  • the process of the present invention allows the attainment of LMW-K5-O-sulfates in controlled manner in order to obtain the mean molecular weight desired and, above all, a well defined sulfation degree which can range from 2.3 to 3 but which can regularly be 2.7-2.9.
  • all the products of the process of the present invention, in particular the free intermediate amines and the N-acyl-K5-amine-O-oversulfates are useful active ingredients for pharmaceutical or cosmetic compositions.
  • the starting materials of step (a) are (epi)K5-N-sulfate-derivatives known in literature or their moieties, or LMW-(epi)K5-N-sulfates prepared by nitrous depolymerization of the corresponding (epi)K5-sulfates.
  • the starting (epi)K5-N-sulfate-derivatives have a mean molecular weight from approximately 1,000 to approximately 25,000, advantageously from approximately 1.500 to approximately 25,000.
  • a lmwepiK5-N-sulfate having an iduronic units content of approximately 20%, obtained by N-deacetylotion, N-sulfation and C5-epimerization of a moiety of K5 having a mean molecular weight of 5,000 is described in WO 92/17507, but this product contains a high percentage of acetyl groups.
  • An epiK5-N-sulfate particularly advantageous as starting material is that obtained by epimerization of a K5-N-sulfate virtually free of acetyl groups in turn prepared from particularly pure K5, in particular not containing lipophilic substances, described in WO 02/068477.
  • the low molecular weight C5-epimerized K5-N-sulfates having a higher content of iduronic units, in particular 40-60%, preferably 50-55%, are instead particularly advantageous new products as starting materials in the preparation of the N-substituted epiK5-amine-O-oversulfated-derivatives of the present invention.
  • the LMW-epiK5-N-sulfates con also be obtained by C5-epimerization of the corresponding LMW-K5-N-sulfates, preferably when their mean molecular weight is more than 4,000.
  • the LMW-K5-N-sulfates virtually free of acetyl groups are all new products preparable by fractionation or, preferably, by depolymerization of a K5-N-sulfate free of acetyl groups.
  • the K5-N-sulfate is well known in literature and is described in documents cited herein above to illustrate the state of the art.
  • the new LMW-epiK5-N-sulfates as shown above are prepared by a process characterized in that a K5-N-sulfate is subjected, in any one order,
  • the expression “in any order” shows that the process can be indifferently carried out both in the direction (i)-(ii), i.e. in the sequence above indicated, and in the reverse direction, i.e. also in the direction (ii)-(i), subjecting the K5-N-sulfate at first to the nitrous depolymerization reaction, optionally followed by reduction with sodium borohydride, and afterwards to the C5-epimerization in the aforesaid conditions.
  • the preferred order is in the direction (i) ⁇ (ii).
  • the sequence (ii)-(i) is preferably utilized starting with LMW-K5-N-sulfates having a mean molecular weight of more than 4000, preferably starting with approximately 6,000.
  • step (ii) the percentage of optimum epimerization is obtained.
  • the C-5epimerization reaction is carried out by recirculating 20-1,000 ml of a solution of 25 mM HEPES at a pH of approximately 7 containing 0.001-10 g of substrate (K5-N-sulfate or LMW-K5-N-sulfate, preferably with a molecular weight of more than 4,000, in particular of at least 6,000) and a cation selected among calcium, magnesium, barium and manganese at a concentration between 10 and 60 mM through a column containing from 1.2 ⁇ 10 7 to 3 ⁇ 10 11 cpm of the immobilized enzyme, maintaining the pH at approximately 7 at approximately 30° C., at a flow of 30-220 ml/hour for a time period of 12-24 hours, advantageously of 15-24 hours.
  • substrate K5-N-sulfate or LMW-K5-N-sulfate, preferably with a molecular weight of more than 4,000, in particular of at least 6,000
  • the nitrous depolymerization reaction is carried out according to known methods by the depolymerization of heparin, for example according to the method described in EP 37319, in WO 82/03627 or according to the method by depolymerization of a K5-N-sulfate described in EP 544592, but starting with a K5-N-sulfate or an epiK5-N-sulfate containing from 0 to no more than 10%, preferably no more than 5%, of acetyl groups.
  • the depolymerization, performed with sodium nitrite and hydrochloric acid on an epiK5-N-sulfate virtually free of acetyl groups is followed by in situ reduction with sodium borohydride.
  • a cold aqueous solution of epiK5-N-sulfate is brought to acid pH (approximately 2) with hydrochloric acid and, still cold, treated with sodium nitrite maintaining the temperature (approximately 4° C.) and the pH (approximately 2) constant and, upon termination of depolymerization (approximately 15-30 minutes) the solution is neutralized with sodium hydroxide and treated, still at approximately 4° C., with an aqueous solution of sodium borohydride.
  • the excess sodium borohydride is destroyed with hydrochloric acid, the solution is neutralized with sodium hydroxide and the depolymerized (and reduced) product is isolated according to known methods, for example by straightforward precipitation with ethanol or acetone.
  • the product obtained upon termination of the depolymerization can be either a lmw-epiK5-N-sulfate (in such case it constitutes the end product) or a lmw-K5-N-sulfate (and in such case is directly subjected to C5-epimerization as shown herein above, after isolation or also in solution without being previously isolated), in particular when it has a mean molecular weight of more than 4,000, preferably of at least 6,000, or is utilized to prepare LMW-K5-N,O-oversulfated of antiangiogenetic and antiviral activity.
  • LMW-K5-N-sulfates or LMW-epiK5-N-sulfates are obtained having a mean molecular weight in the entire interval from approximately 1,500 to approximately 12,000, advantageously from approximately 1,500 to approximately 10,000, preferably from approximately 1,500 to approximately 7,500, calculated at the 13 C-RMN spectrum through the integration of the signal attributed to the C2 of the 2,5-anhydromannitol with that of the anomeric carbon of the glucosamine inside the polysaccharide chain.
  • the amounts of sodium nitrite can be determined which, starting with 1 g of K5-N-sulfate or of epiK5-N-sulfate, allow the attainment of a lmw-K5-N-sulfate or a lmw-epiK5-N-sulfate with a mean molecular weight from approximately 4,000 to approximately 12,000, advantageously from approximately 4,000 to approximately 7,500, in particular of 6,000-7,500.
  • the starting materials in the preparation of the N-acyl-(epi)K5-amine-O-oversulfate-derivatives of the present invention are (epi)K5-N-sulfate-derivatives consisting of a chain mixture in which at least 90% of said chains have the formula I in which the glucuronic units/iduronic units ratio is from 100/0 to 40/60, n is a integer from 2 to 100, advantageously from 3 to 100, and the corresponding cation is chemically or pharmaceutically acceptable.
  • Preferred starting materials are LMW-(epi)K5-N-sulfates consisting of a chain mixture in which at least 90% of said chains have the formula I in which the uronic units are all consisting of glucuronic acid or are 40-60% comprised, preferably 50-55%, of iduronic acid, n is a integer from 2 to 20, advantageously from 3 to 15 and the corresponding cation is chemically acceptable.
  • the epiK5-N-sulfates, prepared by C5-epimerization of K5-N-sulfates, are well known and widely described in literature.
  • a K5-N-sulfate is used obtained from a K5 free of lipophilic substances as described in WO 02/068477 and the C5 epimerization is performed with a D-glucuronyl C5-epimerase isolated, purified and immobilized on a solid support, at a pH of approximately 7, at a temperature of approximately 30° C. and for a time period of 12-24 hours in the presence of at least one bivalent ion selected among calcium, magnesium, barium and manganese as shown above. Also the K5-N-sulfate was shown herein above.
  • the completely N-sulfated (epi)K5-N-sulfates of low molecular weight are instead all particularly advantageous new products as starting materials in the preparation of the N-acyl-(epi)K5-amine-O-oversulfate-derivatives according to the present invention.
  • the term “chemically” refers to a cation usable in chemical synthesis, such as the ions sodium, ammonium, (C 1 -C 4 )tetraalkylammonium, or for the purification of the product.
  • the new LMW-(epi)K5-N-sulfates are useful starting materials consisting of a chain mixture in which at least 90% of said chains have the formula I′ herein above, obtained by nitrous depolymerization of the corresponding (epi) K5-N-sulfates shown above and subsequent possible reduction for example with sodium borohydride.
  • the presence of the structure (a) does not have any influence on the chemical characteristics of the (epi)K5-N-sulfates and their derivatives since any sulfations would involve a possible introduction of one or two sulfate groups which would not significantly change however the sulfation degree of the O-sulfated derivatives. Besides, the presence of the structure (a) does not influence biological activity of the products, as demonstrated by ⁇ stergaard P. B. et al. in Thrombosis Research, 1987, 45, 739-749 ( ⁇ stergaard 1987) for heparins of low molecular weight.
  • LMW-(epi)K5-N-sulfates are consisting of chain mixtures in which the preponderant species is a compound of formula I′b in which X is formyl or hydroxymethyl, m is 4, 5 or 6, the corresponding cation is one chemically or pharmaceutically acceptable ion, the uronic units are all of glucuronic acid or the glucuronic and iduronic units are present alternately, starting with a glucuronic or iduronic unit. In such case the Glucuronic/iduronic ratio is from 45/55 to 55/45, i.e. approximately 50/50.
  • LMW-(epi)K5-N-sulfates i.e. the LMW-K5-N-sulfates shown above and, unlike other epiK5-N-sulfates, for example as indicated in WO 92/17507, also the LMW-epiK5-N-sulfates of the present invention, being virtually free of N-acetyl groups, do not have anticoagulant activity and have an interesting activity against the free radicals.
  • the new LMW-K5-N-sulfates and LMW-epiK5-N-sulfates are active ingredients for the preparation of pharmaceutical compositions utilizable as adjuvants in the treatment of ischemic cardiopathy and for the treatment of radiation dermatitis or of cosmetic compositions useful as anti-ageing of the skin.
  • LMW-(epi)K5-N-sulfates shown above are used as starting materials for the O-oversulfation reaction, it is in any case preferred that, in their preparation by nitrous depolymerization as shown above, said depolymerization is followed by the reduction for example with sodium borohydride to give LMW-K5-N-sulfates characterized by terminal units (a) in which X is hydroxymethyl, since according to the process of the present invention said LMW-(epi)K5-N-sulfates are subjected to reactions of sulfation and acylation whose influence, of the 2,5-anhydromannose radical of structure (a) is unknown on the formyl group, in which X represents formyl.
  • Said starting materials are preferably used in sodium salt form, unless a salt is already available with a tertiary or quaternary organic base prepared according to step (a) shown above, preferably the tetrabutylammonium salt.
  • the starting (epi)-K5-N-sulfate-derivatives preferably 100% N-sulfated
  • the present invention refers to new (epi)K5-amine-O-oversulfate-derivatives and their chemically or pharmaceutically acceptable salts, obtainable by a process characterized in that
  • the derivative thus obtained is generally an (epi)K5-amine-O-oversulfate-derivative having a mean molecular weight from approximately 4,500 to approximately 40,000, isolated in sodium salt form which can be transformed into another chemically or pharmaceutically acceptable salt.
  • Particularly advantageous salts are those of alkaline metals, alkaline-earth metals, of ammonium, (C 1 -C 4 )tetraalkylammonium, aluminum and zinc and, among these, the salts of sodium, calcium and tetrabutylammonium are preferred.
  • a K5-N-sulfate-derivative subjecting a K5-N-sulfate-derivative to the aforesaid steps (a) and (b) a K5-amine-O-oversulfate-derivative is obtained having a sulfation degree from 2.2 to 3, advantageously from 2.5 to 3, preferably from 2.7 to 2.9.
  • both derivatives of low molecular weight with a mean molecular weight from approximately 3,000 to approximately 11,500, preferably from approximately 4,500 to approximately 8,500, with a molecular weight distribution of between approximately 1,000 and approximately 15,000, preferably between approximately 2,000 and approximately 10,000 and derivatives of high molecular weight, originating from the unfractionated K5, with a mean molecular weight from approximately 15,000 to approximately 45,000, preferably between approximately 20,000 and approximately 45,000, with a molecular weight distribution from approximately 2,000 to approximately 70,000.
  • the invention provides new active ingredients of pharmaceutical compositions consisting of (epi)K5-amine-O-oversulfate-derivatives consisting of chain mixtures in which at least 90% of said chains have the formula II in which n is a integer from 2 to 100, preferably from 3 to 100, R, R′ and R′′ are hydrogen or SO 3 —, the uronic units are all of glucuronic acid, for a sulfation degree of at least 2.2, advantageously from 2.2 to 3 or from 2.3 to 3, more advantageously from 2.5 to 3, preferably from 2.7 to 2.9, or are 20-60% consisting of iduronic acid, for a sulfation degree of at least 3.4, advantageously of at least 3.5, more advantageously from 3.55 to 4, preferably from 3.55 to 3.8 and the corresponding cation is chemically or pharmaceutically acceptable.
  • Advantageous epiK5-amine-O-oversulfated-derivatives of extremely high degree of sulfation are consisting of a chain mixture in which at least 90% of said chains have the formula II in which the uronic units are 40-60% consisting of iduronic acid, n is a integer from 2 to 100, preferably from 3 to 100, with a mean molecular weight from approximately 2,000 to approximately 40,000, advantageously from approximately 4,500 to approximately 40,000, R is at least 40%, preferably 50-80% SO 3 —, R′ and R′′ are both SO 3 — or one is hydrogen and the other is 5-10% SO 3 — in monosulfate glucuronic acid and 10-15% SO 3 — in monosulfate iduronic acid, the degree of sulfation is more than 3.4 and the corresponding cation is chemically or pharmaceutically acceptable.
  • LMW-epiK5-amine-O-oversulfates consisting of a chain mixture in which the preponderant species has the formula II′a in which p is a integer from 4 to 8, R, R′ and R′′ are as defined above, the degree of sulfation is from 3.55 to 4 and the corresponding cation is chemically or pharmaceutically acceptable.
  • the reducing end of the majority of the chains in said chain mixture is represented by the structure (b′) in which the uronic unit can be glucuronic or iduronic.
  • the preponderant species is a compound of formula II′b in which R, R′ and R′′ are hydrogen or SO 3 —, X′′ is OH or OSO 3 —, m is 4, 5 or 6, the uronic units are 40-60% consisting of iduronic acid, for a degree of sulfation from 3.55 to 4, the iduronic units being present alternately, starting with a glucuronic or iduronic unit, and the corresponding cation is one chemically or pharmaceutically acceptable ion.
  • the invention provides new K5-amine-O-oversulfate-derivatives consisting of chain mixtures in which at least 90% of said chains have the formula III in which n is a integer from 2 to 100, preferably from 3 to 100, R, R′ and R′′ are hydrogen or SO 3 —, the degree of sulfation is at least 2.2, advantageously from 2.2 to 3 or from 2.3 to 3, more advantageously from 2.5 to 3, preferably from 2.7 to 2.9 and the corresponding cation is chemically or pharmaceutically acceptable.
  • Preferred K5-amine-O-oversulfates are the LMW-K5-amine-O-oversulfates consisting of chain mixtures in which at least 90% of said chains have the formula III′ in which q is a integer from 2 to 20, R, R′ and R′′ represent hydrogen or an SO 3 — group, for a sulfation degree of at least 2.2, advantageously from 2.2 to 3 or from 2.3 to 3, more advantageously from 2.5 to 3, preferably from 2.7 to 2.9 and the corresponding cation is one chemically or pharmaceutically acceptable ion.
  • LMW-K5-amine-O-oversulfates consisting of a chain mixture in which the preponderant species has the formula III′a in which p is a integer from 4 to 8, R, R′ and R′′ are as defined above, the degree of sulfation is at least 2.2, advantageously from 2.2 to 3 or from 2.3 to 3, more advantageously from 2.5 to 3, preferably from 2.7 to 2.9 and the corresponding cation is chemically or pharmaceutically acceptable.
  • the origin of the new LMW-K5-amine-O-oversulfated from LMW-K5-sulfates obtained by nitrous depolymerization and subsequent reduction with, for example, sodium borohydride involves, at the reducing end of the majority of the chains in said chain mixture, the presence of a sulfated 2,5-anhydromannitol unit of structure (a′) as shown above, in which R′′ represents hydrogen or SO 3 —.
  • LMW-K5-amine-O-oversulfated are new products useful as intermediates in the preparation of their N-sulfated or N-acylated derivatives but themselves have interesting pharmacological properties, in particular as anti-free radicals and microbicides and, as such, constitute new active ingredients of pharmaceutical compositions which constitute therefore an additional aspect of the present invention.
  • the invention concerns the use of the aforesaid (epi)K5-amine-O-oversulfate-derivatives with a high degree of sulfation for the preparation of new N-substituted epiK5-amine-O-oversulfate-derivatives.
  • N-acyl-(epi)K5-amine-O-oversulfate-derivatives according to the present invention are obtained by subjecting the (epi)K5-amine-O-oversulfate-derivatives to the step (c) of the process of the present invention.
  • the present invention provides new N-acyl (epi) K5-amine-O-oversulfate-derivatives obtainable by a process characterized in that
  • the degree of sulfation of the N-acyl-(epi) K5-amine-O-oversulfate-derivatives as obtained above depends on the configuration of the starting (epi)K5-N-sulfate-derivative, since the volume in the disaccharide chain of K5-N-sulfate-derivative, in which the uronic units are comprised exclusively of glucuronic acid, allows a oversulfation which is less than that occurring with the epiK5-N-sulfate-derivative, especially if the epimerization degree of the latter is 40-60% of glucuronic acid and 60-40% of iduronic acid.
  • N-acyl-epiK5-amine-O-oversulfate-derivatives having a sulfation degree of at least 3.4, advantageously of at least 3.5, more advantageously from 3.55 to 4, preferably from 3.55 to 3.8.
  • the present invention provides new N-acyl-(epi)K5-amine-O-oversulfate-derivatives in which the acyl is a (C 2 -C 4 ) carboxylic acid, having a mean molecular weight from approximately 2,000 to approximately 45,000, preferably between approximately 4,500 and approximately 40,000, a degree of sulfation as indicated above, said derivatives being basically inactive on the coagulation parameters but useful active ingredients of pharmaceutical or cosmetic compositions.
  • N-acyl-epiK5-amine-O-oversulfate-derivatives of the present invention as pharmaceutical or cosmetic products it is advantageous to prepare both derivatives of low molecular weight, with a mean molecular weight from approximately 3,000 to approximately 11,500, preferably from approximately 4,500 to approximately 8,500, with a molecular weight distribution of between approximately 1,000 and approximately 15,000, preferably between approximately 2,000 and approximately 10,000 and derivatives of high molecular weight, originating from the unfractionated K5, with a mean molecular weight from approximately 15,000 to approximately 45,000, preferably between approximately 20,000 and approximately 45,000, with a molecular weight distribution from approximately 2,000 to approximately 70,000.
  • the degree of sulfation is very high, since on the 4 free hydroxyls available per disaccharide unit, at least 3.4, preferably from 3.5 to 3.8, are sulfated, whereas the nitrogen of the glucosamine is virtually 100% acylated.
  • N-acyl-K5-amine-O-oversulfate-derivatives which, as indicated above, have a degree of sulfation from 2.2 to 3, are at least 90% 6-O-sulfated.
  • the invention provides new N-acyl-epiK5-amine-O-oversulfate-derivatives consisting of chain mixtures in which at least 90% of said chains have the formula IV in which the uronic units are 20-60% consisting of iduronic acid, n is a integer from 2 to 100, preferably from 3 to 100, R, R′ and R′′ are hydrogen or SO 3 —, Z is (C 2 -C 4 )acyl, the degree of sulfation is at least 3.4, advantageously of at least 3.5, more advantageously from 3.55 to 4, preferably from 3.55 to 3.8 and the corresponding cation is chemically or pharmaceutically acceptable.
  • N-acyl-epiK5-amine-O-oversulfate-derivatives of extremely high degree of sulfation are consisting of a chain mixture in which at least 90% of said chains have the formula IV in which the uronic units are 40-60% consisting of iduronic acid, n is a integer from 2 to 100, preferably from 3 to 100, with a mean molecular weight from approximately 2,000 to approximately 45,000, advantageously from approximately 4,500 to approximately 45,000, R is at least 40%, preferably 50-80% SO 3 —, R′ and R′′ are both SO 3 — or one is hydrogen and the other is 5-10% SO 3 — in monosulfate glucuronic acid and 10-15% SO 3 — in monosulfate iduronic acid, the degree of sulfation is more than 3.4 and the corresponding cation is chemically or pharmaceutically acceptable.
  • N-acyl-epiK5-amine-O-oversulfate-derivatives of extremely high degree of sulfation of particular interest are N-acyl-LMW-epiK5-amine-O-oversulfates consisting of a chain mixture in which at least 90% of said chains have the formula IV′ in which q is a integer from 2 to 20, R, R′ and R′′ represent hydrogen or an SO 3 — group for a degree of sulfation from 3.55 to 4, Z is (C 2 -C 4 )acyl, and the corresponding cation is one chemically or pharmaceutically acceptable ion.
  • N-acyl-LMW-epiK5-amine-O-oversulfates are those of very low molecular weight, consisting of a chain mixture in which the preponderant species is a compound of formula IV′a in which p is a integer from 4 to 8, R, R′ and R′′ are hydrogen or an SO 3 — group for a degree of sulfation from 3.55 to 4, Z is (C 2 -C 4 )acyl, and the corresponding cation is one chemically or pharmaceutically acceptable ion.
  • the reducing end of the majority of the chains in said chain mixture is represented by the structure (b′′) in which Z represents (C 2 -C 4 )acyl and the uronic unit can be glucuronic or iduronic.
  • Said cations are advantageously those of alkaline metals, alkaline-earth metals, of ammonium, (C 1 -C 4 )tetraalkylammonium, aluminum and zinc and, among these, preferably the salts of sodium, calcium and tetrabutylammonium.
  • the acyl group (Z) is preferably a (C 2 -C 4 )acyl selected among the group consisting of acetyl, (2-carboxy)acetyl, (2-methoxycarbonyl)acetyl, (2-ethoxycarbonyl)acetyl, propionyl, (3-carboxy) propionyl, N-(3-methoxycarbonyl) propionyl and (3-ethoxycarbonyl) propionyl.
  • the invention provides new N-acyl-K5-amine-O-oversulfate-derivatives consisting of chain mixtures in which at least 90% of said chains have the formula V in which n is a integer from 2 to 100, preferably from 3 to 100, Z is (C 2 -C 4 )acyl, R, R′ and R′′ are hydrogen or SO 3 —, the degree of sulfation is at least 2.2, advantageously from 2.2 to 3 or from 2.3 to 3, more advantageously from 2.5 to 3, preferably from 2.7 to 2.9 and the corresponding cation is chemically or pharmaceutically acceptable.
  • N-acyl-LMW-K5-amine-O-oversulfates consisting of chain mixtures in which at least 90% of said chains have the formula V′ in which q is a integer from 2 to 20, Z is (C 2 -C 4 )acyl, R, R′ and R′′ represent hydrogen or an SO 3 — group for a sulfation degree of at least 2.2, advantageously from 2.2 to 3 or from 2.3 to 3, more advantageously from 2.5 to 3, preferably from 2.7 to 2.9 and the corresponding cation is one chemically or pharmaceutically acceptable ion.
  • N-acyl-LMW-K5-amine-O-oversulfates consisting of a chain mixture in which the preponderant species has the formula V′a in which p is a integer from 4 to 8, Z is (C 2 -C 4 )acyl, R, R′ and R′′ are as defined above, the degree of sulfation is at least 2.2, advantageously from 2.2 to 3 or from 2.3 to 3, more advantageously from 2.5 to 3, preferably from 2.7 to 2.9 and the corresponding cation is chemically or pharmaceutically acceptable.
  • the origin of the new N-acyl-LMW-K5-amine-O-oversulfates from LMW-K5-sulfates obtained by nitrous depolymerization and subsequent reduction with, for example, sodium borohydride involves, at the reducing end of the majority of the chains in said chain mixture, the presence of a sulfated 2,5-anhydromannitol unit of structure (a′) as shown above, in which R′′ represents hydrogen or SO 3 —.
  • N-acyl-LMW-K5-amine-O-oversulfates are preferred those consisting of mixtures in which the preponderant species is a compound of formula V′b in which Z is (C 2 -C 4 )acyl, R, R′ and R′′ are hydrogen or SO 3 —, X′′ is OH or OSO 3 —, for a sulfation degree of at least 2.2, advantageously from 2.2 to 3 or from 2.3 to 3, more advantageously from 2.5 to 3, preferably from 2.7 to 2.9, m is 4, 5 or 6 and the corresponding cation is one chemically or pharmaceutically acceptable ion.
  • the acyl group (Z) is preferably a (C 2 -C 4 )acyl selected among the group consisting of acetyl, (2-carboxy)acetyl, (2-methoxycarbonyl)acetyl, (2-ethoxycorbonyl)acetyl, propionyl, (3-carboxy) propionyl, N-(3-methoxycarbonyl)proponyl and (3-ethoxycarbonyl)proponyl.
  • the new N-acyl-(epi)K5-amine-O-oversulfate-derivatives are highly anionic products able to capture the free radicals. These can be used in the cosmetics industry as coadjuvants against hair loss or to prepare “anti-ageing” creams, but are above all useful in the pharmaceutical industry, as products for the treatment of dermatitis and as microbicides.
  • the present invention provides pharmaceutical compositions including, as one of their active ingredients, a pharmacologically active amount of an N-acyl-(epi)K5-amine-O-oversulfate-derivative as shown above or of one of its pharmaceutically acceptable salts, in mixture with a pharmaceutical excipient.
  • the active ingredients are preferably administered in the form of dosage units, in mixture with the classic pharmaceutical excipients or vehicles.
  • the dose regimen can vary widely depending on the age, the weight and health condition of the patient. This dose regimen includes the administration of a dose from 1 to 1000 mg, advantageously from 10 to 750 mg, preferably 250 to 500 mg from one to three times a day by intravenous, subcutaneous, oral, transdermal or topical administration.
  • the present invention also provides a cosmetic composition including an effective amount of an N-acyl-(epi)K5-amine-O-oversulfated-derivative or one of its pharmaceutically acceptable salts, in mixture with a cosmetic excipient.
  • the present invention provides a pharmaceutical composition including, as one of its active ingredients, an (epi)K5-amine-O-oversulfate-derivative obtainable according to steps (a) and (b) of the process described above, or one of its pharmaceutically acceptable salts, in mixture with a pharmaceutical excipient.
  • said (epi)K5-amine-O-oversulfate-derivative is consisting of a chain mixture in which at least 90% of said chains have the formula II, II′, III or III′ or in which the preponderant species is a compound of formula IIa, II′a, III′a or III′b.
  • Preferred active ingredient is a lmw-K5-amine-O-oversulfate having a degree of sulfation from 2.2 to 3, advantageously having a mean molecular weight from approximately 3,500 to approximately 11,000, more advantageously from approximately 3,500 to approximately 5,200 and basically free of N-acetyl and N-sulfate groups.
  • the active ingredients (epi) K5-amine-O-oversulfate-derivatives are preferably administered in the form of dosage units, in mixture with the classic pharmaceutical excipients or vehicles.
  • the dose regimen can vary widely depending on the age, the weight and health condition of the patient.
  • This dose regimen includes the administration of a dose of an (epi)K5-amine-O-oversulfate-derivative from 1 to 1000 mg, advantageously from 10 to 750 mg, preferably 250 to 500 mg from one to three times a day by intravenous, subcutaneous, oral, transdermal or topical administration.
  • compositions including an (epi)K5-amine-O-oversulfate-derivative such as those shown above are formulated with the classic excipients suitable for different ways of administration.
  • formulations in the form of creams, ointments, liniments, gels, foams, balsams, vaginal pessaries, suppositories, solutions or suspensions suitable for local administration.
  • the present invention provides a pharmaceutical composition containing, as one of its active ingredients, a pharmacologically active amount of a lmw-(epi)K5-N-sulfate, i.e. of a lmw-K5-N-sulfate or of a lmw-epiK5-N-sulfate as shown above or of one of their pharmaceutically acceptable salts, in mixture with a pharmaceutical excipient.
  • a lmw-(epi)K5-N-sulfate i.e. of a lmw-K5-N-sulfate or of a lmw-epiK5-N-sulfate as shown above or of one of their pharmaceutically acceptable salts, in mixture with a pharmaceutical excipient.
  • the active ingredients are preferably administered in the form of dosage units, in mixture with the classic pharmaceutical excipients or vehicles.
  • the dose regimen can vary widely depending on the age, the weight and health condition of the patient. This dose regimen includes the administration of a dose from 1 to 1000 mg, advantageously from 10 to 750 mg, preferably 250 to 500 mg from one to three times a day by intravenous, subcutaneous, oral, transdermal or topical administration.
  • said LMW-(epi)K5-N-sulfate-derivative is consisting of a chain mixture in which at least 90% of said chains have the formula I, or I′, or in which the preponderant species is a compound of formula I′a, or I′b.
  • Preferred active ingredient is a lmw-(epi)K5-N-sulfate-derivative having a mean molecular weight from approximately 1,000 to approximately 12,000, advantageously from approximately 1,500 to approximately 8,000, preferably from approximately 1,500 to approximately 7,500 and basically free of N-acetyl groups.
  • An epimerized product is obtained with an iduronic acid/glucuronic acid ratio of 55/45 against a ratio of 0/100 of the starting product.
  • the percentage of epimerization was calculated with 1 H-RMN according to the method described in WO 96/14425.
  • the yield, calculated by measuring the content of uronic acids against a standard with the carbazole method (Bitter and Muir Anal. Biochem. 39, 88-92-1971) is 90%.
  • 1 g of product obtained in step (a) is depolymerized by the degradation method with nitrous acid and subsequent reduction of the aldehyde which forms.
  • the solution is then brought to 4° C. and the pH to 2 with 0.1 N HCl and maintained for 30 minutes.
  • the solution is brought to room temperature and the pH to 7 with 0.1 M NaOH.
  • the solution is then added with 450 mg. of NaBH 4 and reacted for 4 hours.
  • the product is recovered by precipitation with 3 volumes of acetone at 4° C., filtration with filtering funnel and dried at 40° C.
  • LMW-epiK5-N-sulfate are obtained with a molecular weight distribution measured with HPLC method which ranges from 1,000 to 4,000 and with a glucuronic unit content of 45% and iduronic unit content of 55%.
  • step (a) 1 g of LMW-K5 N-sulfate obtained in step (a) is treated as described in step (a) of the Example 1.
  • An epimerized product is obtained with an iduronic acid/glucuronic acid ratio of 44/56 against a ratio of 0/100 of the starting product, with a molecular weight distribution from 2,000 to 10,000 and with a mean molecular weight of 5,000 D.
  • the yield calculated by measuring the content of uronic acids against a standard with the carbazole method (Bitter and Muir Anal. Biochem. 39, 88-92-1971) is 90%.
  • a solution of 10 g of K5-N-sulfate obtained as described in Example 1, steps (i) and (ii), of WO 02/068477 in 600 ml of 25 mM HEPES buffer at pH 7, containing CaCl 2 at a concentration of 50 mM is made to recirculate through a 50 ml column filled with Sepharose 4B resin containing 5 g of recombinant C5-epimerase (WO 96/14425) immobilized as described in WO 01/72848.
  • the reaction is carried out at 30° C. at pH 7 with a flow of 200 ml/h for 24 hours.
  • the product obtained is purified by ultrafiltration and precipitation with ethanol.
  • an epiK5-N-sulfate is obtained whose iduronic acid content is 54%.
  • 1 g of product obtained in PREPARATION IV is depolymerized by the degradation method with nitrous acid and subsequent reduction of the aldehyde which forms.
  • the solution is then brought to 4° C. and the pH to 2 with 0.1 N HCl and maintained for 30 minutes. At the end of the reaction the solution is brought to room temperature and the pH to 7 with 0.1 M NaOH.
  • the solution is then added with 450 mg. of NaBH 4 and reacted for 4 hours.
  • the product is recovered by precipitation with 3 volumes of acetone at 4° C., filtration with filtering funnel and dried at 40° C. in a vacuum oven.
  • 900 mg of LMW-epiK5-N-sulfate are obtained with a molecular weight distribution measured with HPLC method which ranges from 1,000 to 4,000.
  • a solution of 400 mg of epiK5-N-sulfate with an iduronic acid content of 54% as obtained in PREPARATION IV in 40 ml of water is thermostated at 4° C., then passed over an ionic exchange resin IR 120H + preconditioned with water at 4° C.
  • the eluate obtained consisting of 100 ml of a solution at pH 1.94, is neutralized with a solution of 15% tetrabutylammonium hydroxide and left at room temperature for one hour, maintaining the pH at 7 by addition of 15% tetrabutylammonium hydroxide and finally is lyophilized.
  • 805 mg of tetrabutylammonium salt of epiK5-N-sulfate are obtained.
  • 550 mg of epi-K5-amine-O-oversulfated are obtained having a content of iduronic acid of 54%, of glucosamine-6-O-sulfate of 100%, of glucosamine 3-O-sulfate of 60%, of monosulfate glucuronic acid of 10%, of monosulfate iduronic acid of 15%, the rest of the uronic units being disulfated, with a sulfation degree of 3.55 measured with the conductometric method according to Casu et al. 1975.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
US10/518,303 2002-06-18 2003-06-17 Process for the manufacture of n-acyl-(epi)k5-amine-o-sulfate-derivatives and products thus obtained Abandoned US20050256079A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US12/120,167 US8513407B2 (en) 2002-06-18 2008-05-13 Process for the preparation of N-acyl-(epi)K5-amine-O-sulfate-derivatives and products thus obtained
US14/328,271 US9346893B2 (en) 2002-06-18 2014-07-10 Process for the preparation of highly O-sulfated, epimerized derivatives of K5 polysacchride and intermediates therein

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
ITMI2002A001346 2002-06-18
IT2002MI001346A ITMI20021346A1 (it) 2002-06-18 2002-06-18 Polisaccaridi a basso peso molecolare e procedimento per la loro preparazione
IT2002MI001345A ITMI20021345A1 (it) 2002-06-18 2002-06-18 Derivati epimerizzati del polissacaride k5 a elevatissimo grado di solfatazione
ITMI2002A001345 2002-06-18
ITMI2002A001854 2002-08-27
ITMI20021854 ITMI20021854A1 (it) 2002-08-27 2002-08-27 Polisaccaride supersolfatato a basso peso molecolare.
PCT/IB2003/002339 WO2003106505A1 (en) 2002-06-18 2003-06-17 Process for the manufacture of n-acyl-(epi)k5-amine-o-sulfate-derivatives and products thus obtained

Related Parent Applications (3)

Application Number Title Priority Date Filing Date
PCT/IB2003/002339 A-371-Of-International WO2003106505A1 (en) 2002-06-18 2003-06-17 Process for the manufacture of n-acyl-(epi)k5-amine-o-sulfate-derivatives and products thus obtained
PCT/IB2004/004128 Continuation-In-Part WO2005058976A2 (en) 2002-06-18 2004-12-15 Low molecular polysaccharides having antithrombotic activity
US11/582,687 Continuation-In-Part US7531515B2 (en) 2000-04-05 2006-10-17 Peptides selectively lethal to malignant and transformed mammalian cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/120,167 Continuation-In-Part US8513407B2 (en) 2002-06-18 2008-05-13 Process for the preparation of N-acyl-(epi)K5-amine-O-sulfate-derivatives and products thus obtained

Publications (1)

Publication Number Publication Date
US20050256079A1 true US20050256079A1 (en) 2005-11-17

Family

ID=29740492

Family Applications (4)

Application Number Title Priority Date Filing Date
US10/518,229 Abandoned US20050245736A1 (en) 2002-06-18 2003-06-17 Low molecular weight oversulfated polysaccharide
US10/518,302 Expired - Fee Related US7838644B2 (en) 2002-06-18 2003-06-17 Epimerized derivatives of K5 polysaccharide with a very high degree of sulfation
US10/518,303 Abandoned US20050256079A1 (en) 2002-06-18 2003-06-17 Process for the manufacture of n-acyl-(epi)k5-amine-o-sulfate-derivatives and products thus obtained
US12/895,894 Expired - Fee Related US8193166B2 (en) 2002-06-18 2010-10-01 Epimerized derivatives of K5 polysaccharide with a very high degree of sulfation

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US10/518,229 Abandoned US20050245736A1 (en) 2002-06-18 2003-06-17 Low molecular weight oversulfated polysaccharide
US10/518,302 Expired - Fee Related US7838644B2 (en) 2002-06-18 2003-06-17 Epimerized derivatives of K5 polysaccharide with a very high degree of sulfation

Family Applications After (1)

Application Number Title Priority Date Filing Date
US12/895,894 Expired - Fee Related US8193166B2 (en) 2002-06-18 2010-10-01 Epimerized derivatives of K5 polysaccharide with a very high degree of sulfation

Country Status (15)

Country Link
US (4) US20050245736A1 (es)
EP (3) EP1513880B1 (es)
JP (3) JP5053512B2 (es)
CN (3) CN1675250B (es)
AT (1) ATE485308T1 (es)
AU (3) AU2003240190B2 (es)
BR (3) BR0312197A (es)
CA (3) CA2489866A1 (es)
DE (1) DE60334617D1 (es)
IL (2) IL165808A0 (es)
MX (3) MXPA04012721A (es)
NO (3) NO20050244L (es)
NZ (3) NZ537215A (es)
PL (3) PL375088A1 (es)
WO (3) WO2003106505A1 (es)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070259833A1 (en) * 2004-06-14 2007-11-08 Institut Francais De Recherche Pour L'exploitation De La Mer (Fremer) Use of Low-Molecular-Weight Highly Sulfated Polysaccharide Derivatives for Modulating Angiogenesis
US20080146793A1 (en) * 2001-02-27 2008-06-19 Pasqua Oreste Highly sulfated derivatives of K5 polysaccharide and their preparation
US20090005341A1 (en) * 2002-06-18 2009-01-01 Glycores 2000 S.R.L. Process for the preparation of n-acyl-(epi)k5-amine-o-sulfate-derivatives and products thus obtained
US7812151B2 (en) 2003-12-17 2010-10-12 Glycores 2000 S.R.L. Low molecular weight polysaccharides having antithrombotic activity

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003106505A1 (en) * 2002-06-18 2003-12-24 Pasqua Anna Oreste Process for the manufacture of n-acyl-(epi)k5-amine-o-sulfate-derivatives and products thus obtained
US20120253029A1 (en) 2002-06-18 2012-10-04 Pasqua Anna Oreste Process for the preparation of highly o-sulfated epimerized derivatives of k5 polysaccharide and intermediates therein
ITMI20031618A1 (it) * 2003-08-06 2005-02-07 Inalco Spa Derivati polisaccaridici dotati di alta attivita'
FR2871476B1 (fr) * 2004-06-14 2011-04-01 Ifremer Derives depolymerises sulfates d'exopolysaccharides (eps) provenant de bacteries marines mesophiles, leur procede de preparation et leurs utilisations en regeneration tissulaire
EP1951260A4 (en) 2005-10-21 2009-11-11 Bezwada Biomedical Llc FUNCTIONALIZED PHENOLIC COMPOUNDS AND POURABLE ARTICLES THEREOF

Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4369256A (en) * 1980-04-18 1983-01-18 Crinos Industria Farmacobiologica S.P.A. Polyalkylene resins crosslinked with diisocyanate used for selective separation of heparin from other glucosaminoglycanes
US5110918A (en) * 1986-05-16 1992-05-05 Sanofi S.A. Process for preparing EDTA-free heparins, heparin fractions and fragments
US5550116A (en) * 1990-12-03 1996-08-27 Sanofi N,O-sulphated heparosans and pharmaceutical compositions containing them
US5958899A (en) * 1994-11-04 1999-09-28 Inalco S.P.A. Polysaccharides having a high iduronic acid content
US6162797A (en) * 1996-05-10 2000-12-19 Inalco S.P.A. Derivatives of K5 polysaccharide having high anticoagulant activity
US6288044B1 (en) * 1997-02-07 2001-09-11 Inalco S.P.A. O-sulfated bacterial polysaccharides
US6329351B1 (en) * 1997-08-28 2001-12-11 Istituto Scientifico Di Chimica E Biochimica “G. Ronzoni” Semi-synthetic sulphaminoheparosansulphates having high anti-metastatic activity and reduced haemorrhagic risk
US20020062019A1 (en) * 2000-03-30 2002-05-23 Pasqua Oreste Glycosaminoglycans derived from K5 polysaccharide having high anticoagulant and antithrombotic activities and process for their preparation
US20030023079A1 (en) * 2000-03-30 2003-01-30 Pasqua Oreste Polysaccharides derived from K5 polysaccharide having high anticoagulant and antithrombotic activities and process for their preparation
US20030100534A1 (en) * 2001-10-22 2003-05-29 Giorgio Zoppetti Process for the preparation of chondroitin sulfates from K4 polysaccharide and obtained products
US20030232785A1 (en) * 2002-06-12 2003-12-18 Marco Manoni O-sulphated bacterial polysaccharides and their use
US20040077848A1 (en) * 2001-02-27 2004-04-22 Pasqua Oreste Highly sulfated derivatives of K5 polysaccharide and their preparation
US20050009780A1 (en) * 2001-07-27 2005-01-13 Giorgio Zoppetti Use of oversulfated polysaccharides as inhibitors of hiv
US20050027117A1 (en) * 2000-12-18 2005-02-03 Pasqua Oreste Anticoagulant and antithrombotic LMW-glycosaminoglycans derived from K5 polysaccharide and process for their preparation
US20050142194A1 (en) * 2003-12-30 2005-06-30 Altergon S.A. Composition comprising CS
US20050245736A1 (en) * 2002-06-18 2005-11-03 Oreste Pasqua A Low molecular weight oversulfated polysaccharide
US20070155694A1 (en) * 2003-12-17 2007-07-05 Glycores 2000 S.R.L. Low molecular weight polysaccharides having antithrombotic activity

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2503714B1 (fr) * 1981-04-10 1986-11-21 Choay Sa Procede d'obtention de mucopolysaccharides biologiquement actifs, de purete elevee, par depolymerisation de l'heparine
EP0333243A3 (en) * 1988-03-10 1989-09-27 Akzo N.V. Sulphated k5 antigen and sulphated k5 antigen fragments
GB2254083A (en) 1991-03-28 1992-09-30 Italfarmaco Spa Anticoagulants from e.coli saccharide
FR2684385B1 (fr) * 1991-11-28 1997-08-01 Sanofi Elf Heparosanes-n,o-sulfates de haute masse moleculaire, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5798356A (en) * 1995-08-07 1998-08-25 Alcon Laboratories, Inc. Angiostatic compounds
IT1284143B1 (it) * 1996-09-06 1998-05-08 Istituto Scient Di Chimica E B Eparansolfati semi-sintetici ad elevata attivita' antimetastica e ridotto rischio emorragico
GB9620459D0 (en) 1996-10-01 1996-11-20 Mclaughlin Andrew Improvements in or relating to blocked isocyanates and their production
IT1290814B1 (it) * 1997-03-24 1998-12-11 Istituto Scient Di Chimica E B Glicosaminoglicani aventi elevata attivita' antitrombotica
US6388060B1 (en) * 1998-11-06 2002-05-14 Vascular Therapeutics Inc. Process for the sulfation of uronic acid-containing polysaccharides
ITMI20010779A1 (it) * 2001-04-12 2002-10-12 Giorgio Zoppetti Uso di polisaccaridi batterici solfati atti all'inibizione dell'angiogenesi

Patent Citations (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4369256A (en) * 1980-04-18 1983-01-18 Crinos Industria Farmacobiologica S.P.A. Polyalkylene resins crosslinked with diisocyanate used for selective separation of heparin from other glucosaminoglycanes
US4411796A (en) * 1980-04-18 1983-10-25 Crinos Industria Farmabiologica, S.P.A. Polyaminic resin for the selective separation of heparin from other glucosaminoglycanes and method for the preparation thereof
US5110918A (en) * 1986-05-16 1992-05-05 Sanofi S.A. Process for preparing EDTA-free heparins, heparin fractions and fragments
US5550116A (en) * 1990-12-03 1996-08-27 Sanofi N,O-sulphated heparosans and pharmaceutical compositions containing them
US5958899A (en) * 1994-11-04 1999-09-28 Inalco S.P.A. Polysaccharides having a high iduronic acid content
US6162797A (en) * 1996-05-10 2000-12-19 Inalco S.P.A. Derivatives of K5 polysaccharide having high anticoagulant activity
US6288044B1 (en) * 1997-02-07 2001-09-11 Inalco S.P.A. O-sulfated bacterial polysaccharides
US6329351B1 (en) * 1997-08-28 2001-12-11 Istituto Scientifico Di Chimica E Biochimica “G. Ronzoni” Semi-synthetic sulphaminoheparosansulphates having high anti-metastatic activity and reduced haemorrhagic risk
US20020062019A1 (en) * 2000-03-30 2002-05-23 Pasqua Oreste Glycosaminoglycans derived from K5 polysaccharide having high anticoagulant and antithrombotic activities and process for their preparation
US20030023079A1 (en) * 2000-03-30 2003-01-30 Pasqua Oreste Polysaccharides derived from K5 polysaccharide having high anticoagulant and antithrombotic activities and process for their preparation
US20060281152A1 (en) * 2000-03-30 2006-12-14 Giorgio Zoppetti Glycosaminoglycans derived from the K5 polysaccharide having high anticoagulant and antithrombotic activity and process for their preparation
US20050215518A1 (en) * 2000-03-30 2005-09-29 Pasqua Oreste Glycosaminoglycans derived from K5 polysaccharide having high anticoagulant and antithrombotic activities and process for their preparation
US20040146994A1 (en) * 2000-03-30 2004-07-29 Giorgio Zoppetti Glycosaminoglycans derived from the k5 polysaccharide having high anticoagulant and antithrombotic activity and process for their preparation
US20050027117A1 (en) * 2000-12-18 2005-02-03 Pasqua Oreste Anticoagulant and antithrombotic LMW-glycosaminoglycans derived from K5 polysaccharide and process for their preparation
US20040077848A1 (en) * 2001-02-27 2004-04-22 Pasqua Oreste Highly sulfated derivatives of K5 polysaccharide and their preparation
US20050004358A1 (en) * 2001-02-27 2005-01-06 Pasqua Oreste Highly sulfated derivatives of K5 polysaccharide and their preparation
US6992183B2 (en) * 2001-02-27 2006-01-31 Pasqua Oreste Highly sulfated derivatives of K5 polysaccharide and their preparation
US20050009780A1 (en) * 2001-07-27 2005-01-13 Giorgio Zoppetti Use of oversulfated polysaccharides as inhibitors of hiv
US7268122B2 (en) * 2001-07-27 2007-09-11 Fondazione Centro San Raffaele Del Monte Tabor Use of oversulfated polysaccharides as inhibitors of HIV
US6777398B2 (en) * 2001-10-22 2004-08-17 Ibsa Institut Biochimique S.A. Process for the preparation of chondroitin sulfates from K4 polysaccharide and obtained products
US20030100534A1 (en) * 2001-10-22 2003-05-29 Giorgio Zoppetti Process for the preparation of chondroitin sulfates from K4 polysaccharide and obtained products
US20030232785A1 (en) * 2002-06-12 2003-12-18 Marco Manoni O-sulphated bacterial polysaccharides and their use
US20050245736A1 (en) * 2002-06-18 2005-11-03 Oreste Pasqua A Low molecular weight oversulfated polysaccharide
US20060014718A1 (en) * 2002-06-18 2006-01-19 Oreste Pasqua A Epimerized derivatives of k5 polysaccharide with a very high degree of sulfation
US20070155694A1 (en) * 2003-12-17 2007-07-05 Glycores 2000 S.R.L. Low molecular weight polysaccharides having antithrombotic activity
US20050142194A1 (en) * 2003-12-30 2005-06-30 Altergon S.A. Composition comprising CS

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080146793A1 (en) * 2001-02-27 2008-06-19 Pasqua Oreste Highly sulfated derivatives of K5 polysaccharide and their preparation
US20090005341A1 (en) * 2002-06-18 2009-01-01 Glycores 2000 S.R.L. Process for the preparation of n-acyl-(epi)k5-amine-o-sulfate-derivatives and products thus obtained
US8513407B2 (en) 2002-06-18 2013-08-20 Glycores 2000 S.R.L. Process for the preparation of N-acyl-(epi)K5-amine-O-sulfate-derivatives and products thus obtained
US7812151B2 (en) 2003-12-17 2010-10-12 Glycores 2000 S.R.L. Low molecular weight polysaccharides having antithrombotic activity
US20070259833A1 (en) * 2004-06-14 2007-11-08 Institut Francais De Recherche Pour L'exploitation De La Mer (Fremer) Use of Low-Molecular-Weight Highly Sulfated Polysaccharide Derivatives for Modulating Angiogenesis
US20080131472A1 (en) * 2004-06-14 2008-06-05 Universite Rene Descarties Paris 5 Sulfated Depolymerized Derivatives of Exopolysaccharides (Eps) from Mesophilic Marine Bacteria, Method for Preparing Same, and Uses Thereof in Tissue Regeneration
US7833990B2 (en) 2004-06-14 2010-11-16 Institut Francais De Recherche Pour L'exploitation De La Mer (Ifremer) Use of low-molecular-weight highly sulfated polysaccharide derivatives for modulating angiogenesis
US8598142B2 (en) 2004-06-14 2013-12-03 Institut Francais De Recherche Pour L'exploitation De La Mer (Ifremer) Sulfated depolymerized derivatives of expolysaccharides (EPS) from mesophilic marine bacteria, method for preparing the same, and uses thereof in tissue regeneration
US9125883B2 (en) 2004-06-14 2015-09-08 Institut Francais De Recherche Pour L'exploitation De La Mer (Ifremer) Sulfated depolymerized derivatives of exopolysaccharides (EPS) from mesophilic marine bacteria, method for preparing same, and uses thereof in tissue regeneration

Also Published As

Publication number Publication date
JP2005536577A (ja) 2005-12-02
IL165807A0 (en) 2006-01-15
US7838644B2 (en) 2010-11-23
PL375088A1 (en) 2005-11-14
JP5053512B2 (ja) 2012-10-17
AU2003240191A1 (en) 2003-12-31
NZ537217A (en) 2005-09-30
US20110021766A1 (en) 2011-01-27
JP2005533878A (ja) 2005-11-10
US20060014718A1 (en) 2006-01-19
JP2005530877A (ja) 2005-10-13
US8193166B2 (en) 2012-06-05
PL375087A1 (en) 2005-11-14
WO2003106505A9 (en) 2004-02-26
BR0312182A (pt) 2005-04-05
BR0312197A (pt) 2005-04-05
DE60334617D1 (de) 2010-12-02
PL373004A1 (en) 2005-08-08
IL165808A0 (en) 2006-01-15
CA2489862C (en) 2012-03-27
IL165807A (en) 2011-10-31
BR0312179A (pt) 2005-04-05
MXPA04012805A (es) 2005-08-19
EP1519961A1 (en) 2005-04-06
CA2489870A1 (en) 2003-12-24
WO2003106505A1 (en) 2003-12-24
EP1513880B1 (en) 2010-10-20
NO20050244L (no) 2005-03-16
CN1671744A (zh) 2005-09-21
EP1517924A1 (en) 2005-03-30
WO2003106506A1 (en) 2003-12-24
CN1675250A (zh) 2005-09-28
CN1675249A (zh) 2005-09-28
NZ537215A (en) 2006-11-30
MXPA04012721A (es) 2005-08-15
NO20050247L (no) 2005-03-16
NZ537216A (en) 2005-05-27
AU2003242881A1 (en) 2003-12-31
US20050245736A1 (en) 2005-11-03
CA2489862A1 (en) 2003-12-24
MXPA04012714A (es) 2005-08-15
AU2003240190B2 (en) 2009-07-09
ATE485308T1 (de) 2010-11-15
NO20050245L (no) 2005-03-16
CN1675250B (zh) 2012-11-14
WO2003106504A1 (en) 2003-12-24
CA2489866A1 (en) 2003-12-24
AU2003240190A1 (en) 2003-12-31
EP1513880A1 (en) 2005-03-16

Similar Documents

Publication Publication Date Title
US8193166B2 (en) Epimerized derivatives of K5 polysaccharide with a very high degree of sulfation
US8513407B2 (en) Process for the preparation of N-acyl-(epi)K5-amine-O-sulfate-derivatives and products thus obtained
EP1366082B1 (en) Highly sulfated derivatives of k5 polysaccharide and their preparation
US7812151B2 (en) Low molecular weight polysaccharides having antithrombotic activity
US9346893B2 (en) Process for the preparation of highly O-sulfated, epimerized derivatives of K5 polysacchride and intermediates therein
RU2333222C2 (ru) Эпимеризованные производные полисахарида к5 с высокой степенью сульфатирования
ZA200410357B (en) Process for the manufacture on N-acyl-(EPI)K5-amine-o-sulfate-derivatives and products thus obtained.
KR20050024339A (ko) 엔-아실-(에피)케이5-아민-오-황산염-유도체 생산방법 및그 생성물
KR20050024349A (ko) 매우 높은 황산화도를 가진 케이5 폴리사카라이드의에피머화된 유도체

Legal Events

Date Code Title Description
AS Assignment

Owner name: GLYCORES 2000 S.R.L., ITALY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ORESTE, PASQUA ANNA;ZOPPETTI, GIORGIO;REEL/FRAME:016693/0616

Effective date: 20041203

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION